Balloon Angioplasty vs. Sirolimus Eluting Stenting in Infrapopliteal Territory

Original Title: Wound Healing Outcomes and Health-Related Quality-of-Life Changes in the ACHILLES Trial1-Year Results From a Prospective Randomized Controlled Trial of Infrapopliteal Balloon Angioplasty Versus Sirolimus-Eluting Stenting in Patients With Ischemic Peripheral Arterial Disease. Reference: Konstantinos Katsanos et al. J Am Coll Cardiol Intv. 2016, online before print.

 

The ACHILLES study (Comparing Angioplasty and DES in the Treatment of Subjects with Ischemic Infrapopliteal Arterial Disease) was a randomized multicenter study comparing balloon angioplasty vs. sirolimus eluting stenting in infrapopliteal territory.

The study had already reported that sirolimus eluting stenting results in lower restenosis and higher event-free survival rates compared to balloon angioplasty.

This sub study assessed wound healing and quality of life in patients with intermittent claudication and critical ischemia due to infrapopliteal lesions.

A total of 200 patients were randomized to balloon angioplasty vs. sirolimus eluting stenting in infrapatellar occlusive lesions. Wound evolution was assessed by photography and quality of life by standardized questions after one year of randomization.

109 open wounds were documented at baseline (54 received sirolimus eluting stents and 55 balloon angioplasty).

At 6 months, wound volume reduction was significantly higher in patients receiving stents (95% reduction with stents vs. 60% reduction with balloons; p=0.048). At one year, complete wound closure rates were also higher in those receiving sirolimus eluting stents (72.9% vs 55.6%; p=0.088).

Quality of life scored (EQ-5D) significantly higher in those receiving stents (p<0.0001) than those receiving balloons.

Conclusion
Sirolimus eluting stenting in infrapopliteal territory accelerates wound healing and could improve quality of life, compared to balloon angioplasty.

More articles by this author

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...